Blueprint Medicines (NASDAQ: BPMC) reported Q4 EPS of ($1.82), $0.22 better than the analyst estimate of ($2.04). Revenue for the quarter came in at $71.95 million versus the consensus estimate of $66.92 million.

GUIDANCE:

Blueprint Medicines sees FY2024 revenue of $360-390 million, versus the consensus of $391 million.

For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.